Welcome to our dedicated page for Supernus Pharma news (Ticker: SUPN), a resource for investors and traders seeking the latest updates and insights on Supernus Pharma stock.
Supernus Pharmaceuticals, Inc. (SUPN) is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The company’s news flow reflects its role in neurology and psychiatry, with updates on commercial performance, pipeline progress, and strategic transactions.
Recent press releases highlight quarterly financial results, where Supernus reports net product sales for CNS therapies such as Qelbree, GOCOVRI, APOKYN, Trokendi XR, Oxtellar XR, ONAPGO, and other products including MYOBLOC, XADAGO, and Osmolex ER. The company also reports collaboration revenue from ZURZUVAE, an oral treatment for postpartum depression, reflecting its collaboration with Biogen Inc. in the U.S. following Supernus’s acquisition of Sage Therapeutics, Inc.
Investors following SUPN news can expect coverage of product launches and commercialization updates, such as the U.S. launch and demand trends for ONAPGO, described as a subcutaneous apomorphine infusion device for motor fluctuations in adults with advanced Parkinson’s disease. Company announcements also discuss supply constraints and prioritization of existing patients when demand exceeds available inventory.
Supernus regularly issues news about its R&D pipeline, including clinical progress for SPN-817 in epilepsy, SPN-820 in depression, and SPN-443 for ADHD/CNS. In addition, the company announces participation in healthcare and therapeutics conferences hosted by investment banks and other organizations, providing forums where management discusses its CNS portfolio, financial performance, and strategy.
This news page aggregates these disclosures so readers can track earnings releases, collaboration developments around ZURZUVAE, clinical trial updates, and investor conference appearances related to Supernus Pharmaceuticals, Inc. (SUPN).
Supernus Pharmaceuticals reported total revenues of $177.4 million for Q3 2022, a 19% increase year-over-year. The company raised its full-year guidance for operating earnings to $35 million to $45 million and total revenues to $650 million to $680 million. Qelbree prescriptions rose to 94,328, a 50% increase from Q2 2022, with net product sales of $18.3 million. GOCOVRI's sales reached $27.9 million, up 16% from the previous year. Adjusted operating earnings for Q3 were $25.4 million, down from $43.3 million in 2021.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced its upcoming third quarter 2022 financial results, set to be reported after market close on November 8, 2022. CEO Jack Khattar and CFO Tim Dec will host a conference call to discuss the results at 4:30 p.m. ET on the same day.
The call will be available via live webcast on the company's Investor Relations website, where a replay will also be accessible for 60 days following the event.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced that the FDA issued a Complete Response Letter (CRL) for its SPN-830 New Drug Application (NDA). This investigational apomorphine infusion device targets motor fluctuations in Parkinson's disease. The CRL requests further information about labeling, product quality, and device performance. Notably, the FDA's initial findings do not ask for additional efficacy and safety studies. Supernus aims to address the FDA's concerns and expedite the NDA resubmission, which will undergo a six-month review timeline.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced that President and CEO Jack Khattar will participate in a fireside chat at the 2022 Wells Fargo Healthcare Conference on September 7, 2022, at 8:35 a.m. ET. The conference runs from September 7-9, 2022, at Encore Boston Harbor, Massachusetts. Investors can access a live audio webcast of the presentation via the Company’s website, with an archived replay available for 60 days. Supernus focuses on developing treatments for central nervous system diseases.
Supernus Pharmaceuticals reported Q2 2022 revenues of $170.1 million, reflecting a 20% increase year-over-year. The company's GAAP operating earnings stood at $11.3 million, down from $34.1 million in Q2 2021. Notably, Qelbree prescriptions surged to 62,938, marking a 33% increase from Q1 2022. Net product sales for Qelbree grew by 34% quarter-over-quarter, reaching $11.1 million. The company maintains a robust cash position of $508.2 million.
Supernus Pharmaceuticals (Nasdaq: SUPN) has announced the upcoming release of its financial and business results for Q2 2022 on August 4, 2022, after market close. The conference call, hosted by President and CEO Jack Khattar and CFO Tim Dec, will begin at 4:30 p.m. ET. Investors can pre-register for the call and access a live webcast through the company's Investor Relations website. Supernus is focused on CNS disease treatments and is advancing a range of product candidates for various neurological disorders.
Supernus Pharmaceuticals (Nasdaq: SUPN) will present at the Jefferies Healthcare Conference on June 9, 2022, at 10:30 a.m. ET. CEO Jack Khattar will lead the presentation, highlighting the company’s focus on CNS diseases.
Investors can arrange meetings through the conference coordinator. The event occurs from June 8-10, 2022, at the New York Marriott Marquis. A live audio webcast will be available on the company's website, with a replay for 60 days post-conference. Supernus is known for its CNS product portfolio, including treatments for epilepsy, migraines, and Parkinson’s disease.
Supernus Pharmaceuticals reported first quarter 2022 revenues of $152.5 million, a 16% increase year-over-year. Net earnings rose to $25.6 million or $0.43 per diluted share. GAAP operating income stood at $2.0 million, while non-GAAP operating income was $28.0 million, reflecting an 11% increase from 2021. The FDA approved Qelbree® for adult ADHD treatment, contributing to 47,324 prescriptions in Q1, a 38% increase from Q4 2021. Financial guidance for 2022 remains $640 - $680 million in total revenues.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced it will report Q1 2022 financial results after the market closes on May 9, 2022. President and CEO Jack Khattar and CFO Tim Dec will host a conference call at 4:30 p.m. ET to discuss the results, with a Q&A session following. A live webcast will be available on the Supernus website. The company specializes in developing CNS disease treatments, including products for epilepsy, migraine, and Parkinson’s disease.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced FDA approval for Qelbree (viloxazine) to treat ADHD in adults, marking the first new nonstimulant treatment in 20 years. ADHD impacts 10 million adults in the U.S., with up to 90% of diagnosed children continuing into adulthood. The approval follows positive Phase III trial results, demonstrating significant symptom reduction compared to placebo (p=0.0040). Qelbree, a once-daily capsule, has shown a favorable safety profile, but may increase suicidal thoughts in some patients.